- July 28, 2022
- Newsletter
- 617-430-5616
Menu
» Home » CAD » Neurology » Neurodegenerative Diseases » Amyotrophic Lateral Sclerosis
ADVERTISEMENT
ADVERTISEMENT
» Home » CAD » Neurology » Neurodegenerative Diseases » Amyotrophic Lateral Sclerosis
Background
Commonly also known as Lou Gehrig’s Disease, ALS is a disease which causes neurodegeneration of motor neurons. Amyotrophic lateral sclerosis does not have a single proven etiology. Instead, multiple pathways can cause very similar disease entities.
ALS has multiple patterns of onset, affecting both the lower and upper motor neurons, generally beginning with degeneration of the lower motor neurons in the proximal limbs.
ALS is an incurable and progressive disease which leads to paralysis and death. Interventions and medications can prolong life and manage symptoms for up to 10 or more years.
Epidemiology
90%-95% of ALS cases are sporadic, and the remaining have familial causes. ALS is rare worldwide, and within the US, the annual incidence of this condition is 5.2 cases per 100,000 individuals.
Individuals over the age of 40 are more susceptible to illness, and in sporadic ALS the ration of male-females is 1.3-1.5. White-skinned individuals are also more likely to be affected.
Until recently, genetic predisposition and age were the only proven risk factors for this condition, but now there’s significant evidence to suggest that another risk factors might be smoking cigarettes.
Anatomy
Pathophysiology
The pathogenesis of ALS is characterized by axonal deterioration and gliosis of axons in the lateral and anterior spinal cord columns. Eventually there’s a loss of Betz cells of the motor cortex, and motor neurons of the spinal cord.
Bunina bodies are often observed in the motor cells affected by ALS, a feature characteristic to this disease. Most cases of ALS also present with intracellular TDP-43 inclusions, a feature which pathologically links this condition to frontotemporal dementia.
Etiology
Many mechanisms have been hypothesized as the cause of sporadic ALS, but no hypothesis has been proven.
Some of the hypotheses are:
Genetics
There are multiple genetic factors behind familial ALS, the most common of which include mutations of the SOD1 gene, and frequent expansion of the C9ORF72 gene.
Mutated SOD1 protein misfolds and accumulates, causing cellular damage and ultimately apoptosis. Both genetic abnormalities are primarily dominant autosomal traits.
Instead of having a single etiology, ALS is an etiologically complex clinical entity that results from a myriad of distinct potential preceding aberrations.
Prognostic Factors
Most patients diagnosed with ALS survive for 3-5 years, but 30% of individuals live for over 5 years, and 10%-20% for over 10 years since diagnosis.
Some of the factors which suggest a better prognosis are:
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
(Orphan)
Lactobacillus plantarum is designated for the treatment of ALS (Amyotrophic Lateral Sclerosis)
Indicated in patients with the above condition who have SOD1 (superoxide dismutase 1 gene)
100 mg intrathecally as a lumbar puncture
Loading dose- (1 dose every 14 days) x 3 doses
Maintenance dose- Every 28 days
tofersen does not underdo hepatic enzyme metabolism
sodium phenylbutyrate and taurursodiol
Initial dose: one packet containing 1g taurursodiol /3g sodium phenylbutyrate orally daily for first three weeks
Maintenance dose: one packet orally twice a day
Dose Adjustments
Dosage Modifications
Hepatic impairment
Pharmacokinetics have not been studied
Mild: dose adjustment is not necessary; there have been no reports for safety issues in clinical studies.
Moderate/severe: do not use
Renal impairment
Pharmacokinetics have not been studied
Mild: dose adjustment is not necessary; there have been no reports for safety issues in clinical studies.
Moderate/severe: do not use
dextromethorphan/quinidine is indicated as an orphan drug for the above condition
sodium phenylbutyrate/ taurursodiol
Indicated for Amyotrophic Lateral Sclerosis
Initial dose: one packet of 3 gm of sodium phenylbutyrate /1 gm of taurursodiol orally every day for the first 3 weeks
Maintenance dose: one packet orally two times a day
Future Trends
References
https://www.ncbi.nlm.nih.gov/books/NBK556151/
ADVERTISEMENT
» Home » CAD » Neurology » Neurodegenerative Diseases » Amyotrophic Lateral Sclerosis
Commonly also known as Lou Gehrig’s Disease, ALS is a disease which causes neurodegeneration of motor neurons. Amyotrophic lateral sclerosis does not have a single proven etiology. Instead, multiple pathways can cause very similar disease entities.
ALS has multiple patterns of onset, affecting both the lower and upper motor neurons, generally beginning with degeneration of the lower motor neurons in the proximal limbs.
ALS is an incurable and progressive disease which leads to paralysis and death. Interventions and medications can prolong life and manage symptoms for up to 10 or more years.
90%-95% of ALS cases are sporadic, and the remaining have familial causes. ALS is rare worldwide, and within the US, the annual incidence of this condition is 5.2 cases per 100,000 individuals.
Individuals over the age of 40 are more susceptible to illness, and in sporadic ALS the ration of male-females is 1.3-1.5. White-skinned individuals are also more likely to be affected.
Until recently, genetic predisposition and age were the only proven risk factors for this condition, but now there’s significant evidence to suggest that another risk factors might be smoking cigarettes.
The pathogenesis of ALS is characterized by axonal deterioration and gliosis of axons in the lateral and anterior spinal cord columns. Eventually there’s a loss of Betz cells of the motor cortex, and motor neurons of the spinal cord.
Bunina bodies are often observed in the motor cells affected by ALS, a feature characteristic to this disease. Most cases of ALS also present with intracellular TDP-43 inclusions, a feature which pathologically links this condition to frontotemporal dementia.
Many mechanisms have been hypothesized as the cause of sporadic ALS, but no hypothesis has been proven.
Some of the hypotheses are:
There are multiple genetic factors behind familial ALS, the most common of which include mutations of the SOD1 gene, and frequent expansion of the C9ORF72 gene.
Mutated SOD1 protein misfolds and accumulates, causing cellular damage and ultimately apoptosis. Both genetic abnormalities are primarily dominant autosomal traits.
Instead of having a single etiology, ALS is an etiologically complex clinical entity that results from a myriad of distinct potential preceding aberrations.
Most patients diagnosed with ALS survive for 3-5 years, but 30% of individuals live for over 5 years, and 10%-20% for over 10 years since diagnosis.
Some of the factors which suggest a better prognosis are:
(Orphan)
Lactobacillus plantarum is designated for the treatment of ALS (Amyotrophic Lateral Sclerosis)
Indicated in patients with the above condition who have SOD1 (superoxide dismutase 1 gene)
100 mg intrathecally as a lumbar puncture
Loading dose- (1 dose every 14 days) x 3 doses
Maintenance dose- Every 28 days
tofersen does not underdo hepatic enzyme metabolism
sodium phenylbutyrate and taurursodiol
Initial dose: one packet containing 1g taurursodiol /3g sodium phenylbutyrate orally daily for first three weeks
Maintenance dose: one packet orally twice a day
Dose Adjustments
Dosage Modifications
Hepatic impairment
Pharmacokinetics have not been studied
Mild: dose adjustment is not necessary; there have been no reports for safety issues in clinical studies.
Moderate/severe: do not use
Renal impairment
Pharmacokinetics have not been studied
Mild: dose adjustment is not necessary; there have been no reports for safety issues in clinical studies.
Moderate/severe: do not use
dextromethorphan/quinidine is indicated as an orphan drug for the above condition
sodium phenylbutyrate/ taurursodiol
Indicated for Amyotrophic Lateral Sclerosis
Initial dose: one packet of 3 gm of sodium phenylbutyrate /1 gm of taurursodiol orally every day for the first 3 weeks
Maintenance dose: one packet orally two times a day
https://www.ncbi.nlm.nih.gov/books/NBK556151/
Commonly also known as Lou Gehrig’s Disease, ALS is a disease which causes neurodegeneration of motor neurons. Amyotrophic lateral sclerosis does not have a single proven etiology. Instead, multiple pathways can cause very similar disease entities.
ALS has multiple patterns of onset, affecting both the lower and upper motor neurons, generally beginning with degeneration of the lower motor neurons in the proximal limbs.
ALS is an incurable and progressive disease which leads to paralysis and death. Interventions and medications can prolong life and manage symptoms for up to 10 or more years.
90%-95% of ALS cases are sporadic, and the remaining have familial causes. ALS is rare worldwide, and within the US, the annual incidence of this condition is 5.2 cases per 100,000 individuals.
Individuals over the age of 40 are more susceptible to illness, and in sporadic ALS the ration of male-females is 1.3-1.5. White-skinned individuals are also more likely to be affected.
Until recently, genetic predisposition and age were the only proven risk factors for this condition, but now there’s significant evidence to suggest that another risk factors might be smoking cigarettes.
The pathogenesis of ALS is characterized by axonal deterioration and gliosis of axons in the lateral and anterior spinal cord columns. Eventually there’s a loss of Betz cells of the motor cortex, and motor neurons of the spinal cord.
Bunina bodies are often observed in the motor cells affected by ALS, a feature characteristic to this disease. Most cases of ALS also present with intracellular TDP-43 inclusions, a feature which pathologically links this condition to frontotemporal dementia.
Many mechanisms have been hypothesized as the cause of sporadic ALS, but no hypothesis has been proven.
Some of the hypotheses are:
There are multiple genetic factors behind familial ALS, the most common of which include mutations of the SOD1 gene, and frequent expansion of the C9ORF72 gene.
Mutated SOD1 protein misfolds and accumulates, causing cellular damage and ultimately apoptosis. Both genetic abnormalities are primarily dominant autosomal traits.
Instead of having a single etiology, ALS is an etiologically complex clinical entity that results from a myriad of distinct potential preceding aberrations.
Most patients diagnosed with ALS survive for 3-5 years, but 30% of individuals live for over 5 years, and 10%-20% for over 10 years since diagnosis.
Some of the factors which suggest a better prognosis are:
https://www.ncbi.nlm.nih.gov/books/NBK556151/
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.